Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock?

In the past month, Novo Nordisk (NVO) shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic headwinds. A key catalyst was last week’s announcement from rival Eli Lilly (LLY) , which reported first phase III success for its oral GLP-1 candidate, orforglipron, in lowering blood glucose and promoting weight loss in type II diabetes (T2D) patients. Oral pills, being more convenient than injectables, tend to boost patient adherence.Novo Nordisk also markets Rybelsus ...